PAPAP for COVID-19

 PAPAP has been reported as potentially beneficial for COVID-19 in the following study.
COVID-19 involves the interplay of 350+ viral and host proteins and factors providing many therapeutic targets. Scientists have proposed 10,000+ potential treatments. c19early.org analyzes 200+ treatments. We have not reviewed pAPAP in detail.
ABOU-ZEID, L., In Silico #Favipiravir Isostere a Promising Remedy: Lead discovery for Covid-19 remedy. Laila A Abou-Zeid; Associate Professor. FOP, Delta University & Mansoura University, Center for Open Science, doi:10.31219/osf.io/myw67
<p>A newly emerged Human Coronavirus (HCoV) is reported three months ago in Wuhan, China (COVID-19). Based on the World Health Organization (WHO) reports until today more than 4000 deaths from the 114,000 confirmed cases reported. The current study aims to shed light on one of the promising lead against COVID-19.P-Amino-Antineoplastone small molecule that therapeutically evaluated as anticancer is evaluated for its complementarity and recognition at the binding site of the NSP15 endoribonuclease protein that just issued at 3rd of March 2020; at the protein data bank coded 6VWW.Based on the presence of common structural features in both pAPAP and the antiviral drug (Favilavir) that announced as the first line for treatment of positively tested coronavirus patients in China. In silico molecular docking of p-amino-phenylacetyl pipredinedione (pAPAP) in complex with NSP15 showed promising binding affinity that gives great anticipation inhibiting the endoribonuclease COVID19.</p>